U.S. Patent Protection Watch List Doesn’t Match PhRMA’s Wish List
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. Trade Representative places 10 countries on its “priority watch” list, including China and India, and 27 on its “watch list,” including Canada and Turkey; PhRMA requested that India and Turkey be put on the higher “priority foreign country” list and Canada be moved up to the priority watch list.
You may also be interested in...
Rx Pricing Practices Of US Trading Partners Criticized By Trade Office
US Trade Representative also highlights restrictive patentability criteria in Canada, India and Indonesia in its annual Special 301 report.
Canada Patent Protections In Spotlight As PhRMA Seeks Addition To “Priority Watch List”
The drug industry sees a not-so-friendly neighbor to the North and wants help from the Office of the U.S. Trade Representative to get Canada to change its “promise utility doctrine.”
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.